神经病学和神经科学杂志

  • 国际标准期刊号: 2171-6625
  • 期刊 h 指数: 17
  • 期刊引用分数: 4.43
  • 期刊影响因子: 3.38
索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 全球影响因子 (GIF)
  • 中国知网(CNKI)
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 科学期刊影响因子 (SJIF)
  • 欧洲酒吧
  • 谷歌学术
  • 秘密搜索引擎实验室
分享此页面

抽象的

Cerebral Venous Sinus Thrombosis: Incidence and Hyperhomocysteinemia as a Risk Factor in Japanese Patients

Makoto Takemaru, Masaru Kuriyama*, Takahiro Himeno, Yuji Shiga, Yuhei Kanaya, Shinichi Takeshima, Takeshi Yoshimoto, Kazuhiro Takamatsu, Yutaka Shimoe, Shinzo Ohta and Akio Tanaka

Background: Cerebral venous sinus thrombosis (CVT) occurs commonly in young female adults and is caused by various risk factors. Our aim was to determine the incidence, clinical characteristics, and risk factors of Japanese CVT patients.

Patients and methods: We performed a retrospective study of CVT patients from January 2010 to June 2015. In the patients who had hyperhomocysteinemia, vitamin levels were measured. To define the clinical characteristics in patients with hyperhomocysteinemia, we statistically compared them to those patients with normal levels of homocysteine.

Results: Sixteen patients (aged 54.6 ± 17.7 years; 13 men and 3 women) were included. The incidence of CVT was 0.23% among all types of strokes or 0.30% of acute ischemic strokes, which was lower than previously reported. The patients were characterized by advanced age, low frequency of headaches, and few female patients, especially female patients using oral contraceptives. The predisposing conditions included a notably high incidence of hyperhomocysteinemia (56.3%). They also included deficiencies of folate, vitamin B12, vitamin B6, or combined deficiencies. Marked hyperhomocysteinemia over 100 nmol/ml was noted in combined deficiencies.

Conclusions: CVT in Japan commonly occurred in older males. The prevalence of hyperhomocysteinemia as a risk factor of CVT was high, and the main underlying disorders were folate and vitamin B12 or B6 deficiencies. This is clinically important, because these acquired risks can be corrected by supplementation therapy to prevent the recurrence of CVT.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证